Inside PIC/S: Top GMP Deficiencies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside PIC/S: Top GMP Deficiencies
Comparison of the top GMP deficiencies cited by the PIC/S Participating Authorities.


Pharmaceutical Technology
Volume 36, Issue 4, pp. 135-137

Results

Thirty-three out of 39 PIC/S Participating Authorities responded (85%). Seven out of 9 applicants to PIC/S responded (78%). The top most frequently cited categories of GMP deficiencies were:

  • Documentation—manufacturing (24)
  • Design and maintenance of premises (22)
  • Documentation—quality systems (elements / procedures) (20)
  • Personnel issues—training (19)
  • Design and maintenance of equipment (18)
  • Cleaning validation (14)
  • Process validation (14)
  • Product quality review (14)
  • Supplier and contractor audit (13)
  • Calibration of measuring and test equipment(12)
  • Equipment validation (11).

The total number of deficiencies per group of top 10 most frequently cited deficiencies were:

  • Production (99, or 24%)
  • Quality system (82, or 20%)
  • Quality control (59, or 14%)
  • Premises and equipment (58, or 14%)
  • Validation (52, or 12%)
  • Personnel issues (34, or 8%)
  • Materials management (29, or 7%)
  • Regulatory issues (5, or 1%)


Figure 1: Most severe cited GMP deficiencies.
The top most severe GMP deficiencies were (see Figure 1):
  • Design and maintenance of premises (15)
  • Contamination, potential for (chemical, physical, microbial) (12)
  • Design and maintenance of equipment (11)
  • Sterility assurance (9)
  • Batch-release procedures (9)
  • Process validation (9)
  • Cleaning validation (8)
  • Investigation of anomalies (7)
  • Documentation—quality systems (elements/procedures) (7)
  • Regulatory issues—noncompliance with marketing authorization (5)
  • Documentation—manufacturing (5).


Figure 2: Top most severe deficiencies by group.
The total number of deficiencies per group of the top most severe deficiencies were (see Figure 2):
  • Production (44, or 27%)
  • Quality system (32, or 20%)
  • Premises and equipment (28, or 17%)
  • Validation (22, or 14%)
  • Quality control (14, or 9%)
  • Regulatory issues (9, or 6%)
  • Materials management (8, or 5%)
  • Personnel issues (5 or 3%).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here